Also known as: Ubrelvy
Ubrelvy (ubrogepant) is an oral CGRP receptor antagonist approved for the acute treatment of migraine attacks with or without aura in adults. It is used as-needed and is not indicated for preventive migraine treatment. Initial U.S. approval was in 2019 with label updates through 2025.
AbbVie's Q2 2026 revenue hit $16.99 billion, beating estimates, but full-year EPS guidance was cut to $13.97. Growth in immunology and neuroscience continued, and the FAST study on ubrogepant wrapped up.
AbbVie posted record 2025 revenue of $61.2 billion and raised 2026 guidance on Skyrizi and Rinvoq growth. Pipeline advances include Crohn's submissions, obesity data, and European approval for Boey.
AbbVie raised 2026 revenue and EPS guidance after first-quarter results beat estimates, with Skyrizi and Rinvoq driving growth. Humira erosion continued as neuroscience, oncology and pipeline assets supported the outlook.
AbbVie said Skyrizi and Rinvoq generated $26.0 billion in 2025 sales and are expected to exceed $31 billion in 2026. The company said the two immunology drugs continue to offset Humira erosion and drive top-line growth.
AbbVie projects 43-45% earnings growth in 2026 as newer immunology drugs Skyrizi and Rinvoq offset declining Humira sales, while maintaining its 54-year dividend increase streak as a Dividend King.
